Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Cancer Connect
CONTACT
Lead
University of Wisconsin, Madison
With
This is a safety study of 86Y-NM600 and 90Y-NM600 and a dose finding study for 90Y-NM600 in patients with metastatic cancers who are receiving an anti-PD-1 or anti-PD-L1 therapy, have persistent disease that is stable or potentially progressive, and will be continuing anti-PD-1 or anti-PD-L1 therapy for another imaging interval per the treating physician. The imaging agent 86Y-NM600 will be injected, and serial positron-emission tomography (PET)/computed tomography (CT) imaging will be performed to enable dosimetry calculations that will be used to determine eligibility for 90Y-NM600. Phase 1a of the study (dose finding) will enroll 6-24 participants into a 3x3 dose finding plan where 3 participants start at Level 1 (below) and the number of participants with dose limiting toxicities (DLTs) will inform the next 3 participants: * 0/3 Escalate to next higher dose level\* * 1/3 Accrue additional 3 patients at current dose level * 1/3 + 0/3 Escalate to next higher dose level\* * 1/3 + ≥ 1/3 End phase 1a or de-escalate to dose level -1 if at dose level 1 * ≥ 2/3 End phase 1a or de-escalate to dose level -1 if at dose level 1 Dosing Plan: * Level -1: 20 millicurie (mCi) x 1 * Level 1: 35 mCi x1 * Level 2: 70 mCi x1 * Level 3: 105 mCi x1 * Level 4: 140 mCi x1 Phase 1b (expansion cohort) may enroll up to an additional 36 participants (18 into a single dose cohort, 18 into a multi-dose cohort) with metastatic cancer. The primary endpoints are to determine the safety of administering 86Y-NM600 for imaging and 90Y-NM600 for delivering radiation in patients with metastatic cancer who are receiving standard-of-care anti-PD-1 or anti-PD-L1 therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
